Eric Nudleman1, Matthew T Witmer, Szilard Kiss, George A Williams, Jeremy D Wolfe. 1. *Associated Retinal Consultants, Royal Oak, Michigan; †Department of Ophthalmology, Weill Cornell Medical College, New York, New York; and ‡Department of Ophthalmology, Oakland University William Beaumont School of Medicine, Beaumont Eye Institute, Royal Oak, Michigan.
Abstract
PURPOSE: To report an association between central serous chorioretinopathy (CSCR) and exogenous testosterone therapy. METHODS: This is a retrospective case series from two institutions. Patients who presented with fluorescein angiography and optical coherence tomography findings consistent with CSCR were included. All patients were concurrently being treated with exogenous testosterone therapy and lacked other known risk factors for CSCR. RESULTS: Nine patients presented with CSCR after beginning exogenous testosterone therapy. Two patients stopped therapy with resolution of symptoms and subretinal fluid. CONCLUSION: Exogenous testosterone may be an independent risk factor for the development of CSCR.
PURPOSE: To report an association between central serous chorioretinopathy (CSCR) and exogenous testosterone therapy. METHODS: This is a retrospective case series from two institutions. Patients who presented with fluorescein angiography and optical coherence tomography findings consistent with CSCR were included. All patients were concurrently being treated with exogenous testosterone therapy and lacked other known risk factors for CSCR. RESULTS: Nine patients presented with CSCR after beginning exogenous testosterone therapy. Two patients stopped therapy with resolution of symptoms and subretinal fluid. CONCLUSION: Exogenous testosterone may be an independent risk factor for the development of CSCR.